FMCNA’s Novalung ECMO System Receives the US FDA’s Approval for Acute Respiratory and Cardiopulmonary Failure

 FMCNA’s Novalung ECMO System Receives the US FDA’s Approval for Acute Respiratory and Cardiopulmonary Failure

FMCNA’s Novalung ECMO System Receives the US FDA’s Approval for Acute Respiratory and Cardiopulmonary Failure

Shots:

  • The US FDA has cleared the Novalung system which eliminates the need for mechanical ventilation by pumping a person’s blood through an oxygenator for gas exchange
  • Novalung is the first extracorporeal membrane oxygenation (ECMO), approved to provide for more than 6hrs. of use as extracorporeal life support with its anticipated availability in the US in mid-2020
  • The Novalung ECMO system works by pumping and oxygenating a patient’s blood, reducing the stress on the damaged heart and lungs. Novalung is a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as ICU, OT, cardiac catheterization labs and emergency departments

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fresenius Medical Care North America

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post